Results 81 to 90 of about 18,145 (196)

Comparison of the Syringe Preparation Time for Ranibizumab Prefilled Syringe versus Bevacizumab, Ranibizumab, and Aflibercept Vials

Archives of Basic and Clinical Research
Objective: To compare the syringe preparation time for ranibizumab prefilled syringe versus bevacizumab, ranibizumab, and aflibercept vials in routine retinal practice. Methods: The study was conducted retrospectively between July 2019 and February 2021
Ahmet Mehmet Somuncu, Adem Uğurlu, Nurdan Gamze Taşlı, Yücel Karakurt, İbrahim Çiçek   +4 more
doaj   +1 more source

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

Biomedical Papers, 2015
Aims: The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods: Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database.
Oldrich Chrapek, Jiri Jarkovsky, Jan Studnicka, Martin Sin, Petr Kolar, Barbora Jirkova, Ladislav Dusek, Sarka Pitrova, Jiri Rehak   +8 more
doaj   +1 more source

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

, 2018
Kanji Takahashi,1 Masahito Ohji,2 Hiroko Terasaki,3 Shigeru Honda,4 Philippe Margaron,5 Tadhg Guerin,6 Mitsuko Yuzawa,7 On behalf of the EVEREST II Japanese investigators 1Department of Ophthalmology, Kansai Medical University, Osaka, Japan ...
Honda S, Margaron P, Terasaki H, Yuzawa M, Guerin T, Takahashi K, Ohji M   +6 more
core  

Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration:a systematic review and meta-analysis of randomized controlled trials

International Journal of Ophthalmology, 2014
AIM:To compare the efficacy and safety of combination of ranibizumab with photodynamic therapy (PDT) vs ranibizumab monotherapy in the treatment of age-related macular degeneration (AMD).METHODS:The Cochrane Central Register of Controlled Trials (CENTRAL)
Jun-Kang Si, Kai Tang, Hong-Sheng Bi, Da-Dong Guo, Jun-Guo Guo, Yu-Xiang Du, Yan Cui, Xue-Mei Pan, Ying Wen, Xing-Rong Wang   +9 more
doaj   +1 more source

Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization

, 2012
Abdallah A Ellabban, Akitaka Tsujikawa, Ken Ogino, Sotaro Ooto, Kenji Yamashiro, Akio Oishi, Nagahisa YoshimuraDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanPurpose: To study changes in ...
Ellabban AA, Oishi A, Yoshimura N, Ogino K, Tsujikawa A, Yamashiro K, Ooto S   +6 more
core  

Intravitreal Ranibizumab Therapy in Wet Type Macular Degeneration

, 2014
Objectives: To evaluate the efficacy and safety of intravitreal ranibizumab treatment in all types of choroidal neovascularization that developed secondary to age-related macular degeneration.
Hasan Altınkaynak, Ahmet Taylan Yazıcı, Kemal Yüksel, Can Kocasaraç, Leyla Hazar, Hüseyin Dündar   +5 more
core   +1 more source

Ranibizumab [PDF]

Reactions Weekly, 2020
  +5 more sources

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis

, 2018
Luping Wang,1 Canwei Zhang,2 Rui Hua3 1Department of Ophthalmology, University of Bonn, Bonn, Germany; 2Department of Ophthalmology, Weifang Eye Hospital, Weifang, People’s Republic of China; 3Department of Ophthalmology, First Hospital of China ...
Wang LP, Hua R, Zhang CW
core  

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years

Al-Azhar Assiut Medical Journal, 2019
Background Diabetic macular edema (DME) is a common cause of blindness and visual impairment in diabetic patients, which can affect the quality of life.
Abd El-Magid M Tag El-Din
doaj   +1 more source

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, Volume 54, Issue 5, Page 724-726, July 2026.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source